These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18980548)

  • 1. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.
    Engstrom PF;
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First- and second-line therapy of metastatic colorectal cancer.
    Terstriep S; Grothey A
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):921-30. PubMed ID: 16761936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
    Lee JJ; Chu E
    Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms and targeting of colorectal cancer.
    Vanhoefer U
    Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current issues in the targeted therapy of advanced colorectal cancer.
    Knijn N; Tol J; Punt CJ
    Discov Med; 2010 Apr; 9(47):328-36. PubMed ID: 20423677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in chemotherapy against advanced or metastatic colorectal cancer.
    Omura K
    Digestion; 2008; 77 Suppl 1():13-22. PubMed ID: 18204257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
    Van Cutsem E
    Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
    Oestreicher P
    ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived.
    O'Neil BH; Goldberg RM
    Expert Opin Investig Drugs; 2003 Dec; 12(12):1939-49. PubMed ID: 14640938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic colorectal cancer.
    Saletti P; Cavalli F
    Cancer Treat Rev; 2006 Nov; 32(7):557-71. PubMed ID: 16935430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy in colorectal cancer.
    Rajpal S; Venook AP
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
    Khattak MA; Martin H; Davidson A; Phillips M
    Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
    Van Cutsem E; Geboes K
    Best Pract Res Clin Gastroenterol; 2007; 21(6):1089-108. PubMed ID: 18070705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of EGFR and VEGF inhibition.
    Pander J; Gelderblom H; Guchelaar HJ
    Drug Discov Today; 2007 Dec; 12(23-24):1054-60. PubMed ID: 18061885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating targeted agents into therapeutic regimens for patients with resectable colorectal cancer.
    Marshall JL
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S63-6. PubMed ID: 19064409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy.
    Serrano C; Markman B; Tabernero J
    Cancer J; 2010; 16(3):226-34. PubMed ID: 20526101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of anti-vascular endothelial growth factor therapies with cytotoxic chemotherapy in the treatment of colorectal cancer.
    Oliveira SC; Machado KK; Sabbaga J; Hoff PM
    Cancer J; 2010; 16(3):220-5. PubMed ID: 20526100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.